Life Design Station International (PINK:LDSI) reached up 39.13% in morning trading to $.0031 with 25M shares traded. Life Design Station International, Inc. is a music-inspired corporation. The Company empowers artists, producers and other music professionals to reach millions of potential customers. Life Design Station International, through its Internet-based division, develops and directs an innovative global social platform allowing artists from the U.S. and the world to interface collaboratively in order to promote, produce and sell their musical artistry. LDSI's Backstage Vibe™ provides a leading-edge, secure and user-friendly environment for the sale, distribution and securing of world talent from one source. Life Design Station International (OTC Pinks:LDSI) today announced successfully launched its innovative social music platform Backstage Vibe™ over the weekend.
Complete Genomics, Inc. (NASDAQ:GNOM) reached up 14.23% in morning trading to $3.05 with 3.5M shares traded. Through its pioneering sequencing-as-a-service model, Complete provides the most accurate whole human genome sequencing available today. The ease of use and power of Complete's advanced informatics and analysis systems provide genomic information needed to better understand the prevention, diagnosis, and treatment of diseases. Complete Genomics, Inc. (GNOM) ("Complete") today announced that they have entered into a definitive merger agreement. Through this agreement, a wholly-owned U.S. subsidiary of BGI will launch a tender offer to purchase all outstanding shares of common stock of Complete for $3.15 per share in cash, without interest. This price represents approximately a 54% premium to the $2.04 closing price per share of Complete common stock on June 4, 2012, the last trading day prior to Complete's announcement that it was undertaking an evaluation of strategic alternatives to secure the financial resources needed for continued commercialization of its technology.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) reached up 14.22% in morning trading to $1.06 with 3M shares traded. Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. Anthera Pharmaceuticals, Inc. (ANTH) today provided an update on regulatory discussions for the global development of blisibimod. End of Phase 2 discussions with the US Food and Drug Administration (FDA) have been completed and will allow for the submission of Phase 3 protocols and the initiation of registration studies. Earlier in 2012, Anthera received a written response from the European Medicines Agency (EMA) providing similar development feedback for the blisibimod program.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
